The French Competition Authority fines a pharmaceutical laboratory €25 million for delaying entry into the market of the generic version of a drug and for hindering its development through disparagement campaigns (Janssen-cilag / Johnson & Johnson)

KEYWORDS
Reference

French Competition Authority, Janssen-Cilag / Johnson & Johnson, Decision n° 17-D-25, 20 December 2017 (French)

THE FRENCH COMPETITION AUTHORITY FINES A PHARMACEUTICAL LABORATORY EUR 25 MILLION FOR ANTI-GENERIC PRACTICES* On 20 December 2017, the French Competition Authority (the FCA) imposed a EUR 25 million fine on a pharmaceutical laboratory, for delaying entry onto the market of the generic version of Durogesic, and for hindering its development through a disparagement campaign. No public version of the decision is available yet, nonetheless the FCA has already published a detailed press release (available in French). WHAT HAPPENED Durogesic is a powerful opioid analgesic, which active substance is fentanyl, usually prescribed in the form of transdermal patch for the treatment of severe pain, including chronic cancer pain. In 2007, a competing pharmaceutical company launched its generic

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Franklin (Paris)
    France 34 contributions 20772 visits
  • McDermott Will & Emery (Paris)
    France 120 contributions 61832 visits

Quotation

Lionel Lesur, Jacques Buhart, The French Competition Authority fines a pharmaceutical laboratory €25 million for delaying entry into the market of the generic version of a drug and for hindering its development through disparagement campaigns (Janssen-cilag / Johnson & Johnson), 20 December 2017, e-Competitions December 2017, Art. N° 92743

Visites 160

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues